Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health concern with limited effective therapies. Silymarin exhibits hepatoprotective properties, but its utility is limited by poor bioavailability. This study evaluated a novel phytosomal silymarin formulation co-administered with piperine and lecithin, compared to fenofibrate, in an oxytetracycline-induced MASLD rat model. Twenty-five male Wistar rats were allocated into five groups: healthy control, MASLD control, fenofibrate (100&#xa0;mg/kg), silymarin (500&#xa0;mg/kg), or silymarin–piperine–lecithin phytocomplex (500/100/3&#xa0;mg/kg) for 90&#xa0;days. Parameters evaluated included serum liver enzymes, lipid profiles, hepatic histology, and hepatic PPAR-α expression. The phytocomplex formulation significantly reduced serum ALT, AST, ALP, and GGT, improved lipid profiles, and restored hepatic architecture, with MASLD-AS and PPAR-α expression demonstrating a marked reduction in hepatic injury and oxidative stress. The phytocomplex outperformed both fenofibrate and silymarin alone, likely due to enhanced bioavailability and synergistic antioxidant action comparable to fenofibrate treatment. This study demonstrates the potential of a phytosomal silymarin–piperine–lecithin complex as a natural therapeutic avenue for MASLD, outperforming a conventional lipid-lowering agent in this animal model. Future clinical and pharmacokinetic studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月6日

查看全文
  • Magdy Fouad Tawfik,
  • Yasmin Sayed Hussein,
  • Amany Helmy Hasanin,
  • Walaa Baher,
  • Nashwa El-Khazragy,
  • Farouk Guindi Moawad,
  • Mawada Abou El-Khair,
  • Salwa M. El-Sayed

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health concern with limited effective therapies. Silymarin exhibits hepatoprotective properties, but its utility is limited by poor bioavailability. This study evaluated a novel phytosomal silymarin formulation co-administered with piperine and lecithin, compared to fenofibrate, in an oxytetracycline-induced MASLD rat model. Twenty-five male Wistar rats were allocated into five groups: healthy control, MASLD control, fenofibrate (100 mg/kg), silymarin (500 mg/kg), or silymarin–piperine–lecithin phytocomplex (500/100/3 mg/kg) for 90 days. Parameters evaluated included serum liver enzymes, lipid profiles, hepatic histology, and hepatic PPAR-α expression. The phytocomplex formulation significantly reduced serum ALT, AST, ALP, and GGT, improved lipid profiles, and restored hepatic architecture, with MASLD-AS and PPAR-α expression demonstrating a marked reduction in hepatic injury and oxidative stress. The phytocomplex outperformed both fenofibrate and silymarin alone, likely due to enhanced bioavailability and synergistic antioxidant action comparable to fenofibrate treatment. This study demonstrates the potential of a phytosomal silymarin–piperine–lecithin complex as a natural therapeutic avenue for MASLD, outperforming a conventional lipid-lowering agent in this animal model. Future clinical and pharmacokinetic studies are warranted.